Thermo Fisher Scientific’s new facility in Bleiswijk, Netherlands, offers comprehensive cold and ultra-cold storage services for clinical trials and biorepository storage. This cGMP-compliant facility caters to the growing demand for cell and gene therapies, biologics, antibodies, and vaccines.
The facility provides a full range of services, including ambient to cryogenic storage, clinical packaging, labeling, distribution, and clinical QP release. With a team of highly skilled professionals, the site supports both new biotech and established pharmaceutical companies in meeting clinical trial requirements of any scale or phase.
Thermo Fisher’s expertise in managing valuable materials and its proven track record in bioservices and specialty logistics place it in a unique position to accelerate the development of innovative therapies. The Bleiswijk facility has 5,000 square meters of storage space, ancillaries, and cold chain packaging infrastructure.
In line with its sustainability commitment, the facility utilizes solar power, eco-friendly electric heat pumps, and heat recovery technology. This reflects Thermo Fisher’s dedication to providing end-to-end solutions for inclusive and impactful clinical research.
The opening of the Bleiswijk facility complements Thermo Fisher’s other recent expansions, including the biologics manufacturing capacity in St. Louis, the cell therapy manufacturing facility in San Francisco, and the Innovation Lab in Pennsylvania.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
